CN115094001A - 肠膜明串珠菌及其在制备抑制幽门螺杆菌的药物中的应用 - Google Patents
肠膜明串珠菌及其在制备抑制幽门螺杆菌的药物中的应用 Download PDFInfo
- Publication number
- CN115094001A CN115094001A CN202210731354.8A CN202210731354A CN115094001A CN 115094001 A CN115094001 A CN 115094001A CN 202210731354 A CN202210731354 A CN 202210731354A CN 115094001 A CN115094001 A CN 115094001A
- Authority
- CN
- China
- Prior art keywords
- product
- leuconostoc mesenteroides
- glycerol
- helicobacter pylori
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000192130 Leuconostoc mesenteroides Species 0.000 title claims abstract description 105
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 66
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 66
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 12
- 229940079593 drug Drugs 0.000 title description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 133
- 235000011187 glycerol Nutrition 0.000 claims abstract description 45
- 230000000694 effects Effects 0.000 claims abstract description 21
- 108010046334 Urease Proteins 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 51
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 39
- 239000006041 probiotic Substances 0.000 claims description 36
- 235000018291 probiotics Nutrition 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 34
- 230000000529 probiotic effect Effects 0.000 claims description 31
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 28
- 235000019202 steviosides Nutrition 0.000 claims description 28
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 27
- 229940013618 stevioside Drugs 0.000 claims description 27
- 235000020183 skimmed milk Nutrition 0.000 claims description 16
- 239000002243 precursor Substances 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 235000008939 whole milk Nutrition 0.000 claims description 6
- 235000013618 yogurt Nutrition 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 244000228451 Stevia rebaudiana Species 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000013322 soy milk Nutrition 0.000 claims 3
- 239000004383 Steviol glycoside Substances 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 claims 1
- 125000002976 glycerolipid group Chemical group 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229930182488 steviol glycoside Natural products 0.000 claims 1
- 235000019411 steviol glycoside Nutrition 0.000 claims 1
- 150000008144 steviol glycosides Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 17
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 14
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 8
- 229920001353 Dextrin Polymers 0.000 description 7
- 239000004375 Dextrin Substances 0.000 description 7
- 235000019425 dextrin Nutrition 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 6
- 235000006679 Mentha X verticillata Nutrition 0.000 description 6
- 235000002899 Mentha suaveolens Nutrition 0.000 description 6
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 6
- 238000009924 canning Methods 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000004088 foaming agent Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 229940095688 toothpaste product Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 241000186604 Lactobacillus reuteri Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108010062877 Bacteriocins Proteins 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241001468157 Lactobacillus johnsonii Species 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000195627 Chlamydomonadales Species 0.000 description 2
- 240000009108 Chlorella vulgaris Species 0.000 description 2
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000011276 addition treatment Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 235000020192 probiotic milk Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- 241000220433 Albizia Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000756137 Hemerocallis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请提供了一种肠膜明串珠菌(Leuconostoc mesenteroides)CGMCC No.24366,并提供了该菌及其与甘油的组合在抑制幽门螺杆菌中的应用。肠膜明串珠菌CGMCC No.24366可显著抑制幽门螺杆菌的生长(抑菌圈直径12.6mm);也可显著抑制幽门螺旋杆菌脲素酶的活性(抑制率68.3%);与甘油合用,抑制幽门螺杆菌能力显著提高(抑菌圈直径14.4mm);在制备抑制幽门螺杆菌的产品,如食品、保健品和药用辅料等中具有良好的应用前景。
Description
技术领域
本申请属于微生物和胃病治疗技术领域,具体地,本申请提供了一种肠膜明串珠菌,并提供了该菌及其与甘油的组合在抑制幽门螺杆菌中的应用。
背景技术
幽门螺旋杆菌(Helicobacter pylori简称HP)是胃癌、慢性胃炎、消化性溃疡、胃黏膜相关淋巴组织淋巴瘤等疾病的主要病因之一。菌体形态呈螺旋或S形,是能够定植于胃黏膜的微厌氧的革兰阴性杆菌(彭超,谢川,吕农华.幽门螺旋杆菌在胃内定植的相关影响因素[J].中国微生态学杂志,2017,29(3):363-366.)。1982年,澳大利亚西澳大学的临床微生物教授Barry J.Marshall发现了幽门螺旋杆菌,2005年获诺贝尔医学奖。幽门螺旋杆菌感染在家庭内有明显的聚集现象,自愈率几乎为零。1994年,世界卫生组织(WHO)国际癌症研究机构将幽门螺旋杆菌定为Ⅰ类致癌原。全世界有超过50%的人有 HP感染。流行病学调查表明,我国成人中HP感染率达到40%~60%,平均为55%(毛丹丹,傅咏南,卞雪莲,王校.一种抑制幽门螺旋杆菌的复合益生菌组合物及其应用[P]. CN111632084A,2020-09-08)。
随着幽门螺旋杆菌治疗的广泛开展,幽门螺旋杆菌对克拉霉素、甲硝唑和左氧氟沙星 (氟喹诺酮类)的耐药率呈上升趋势(Zhang YX,Zhou LY,Song ZQ,et al.Primaryantibiotic resistance of Helicobacter pylori strains isolated from patientswith dyspeptic symptoms in Beijing:a prospective serial study[J].World JGastroenterol,2015,21(9):2786-2792)。目前,益生菌、黏膜保护剂、中药等非抗生素药物在幽门螺旋杆菌防治成研究热点。益生菌在提高幽门螺旋杆菌根除率及减少药物不良反应方面具有显著优势(Ables A Z,Simon I,Melton E R Update on Helicobacter pyloritreatment[J].Am.Fam.Physician,2007,75:351-358.;Yoon H,Kim N,Kim J Y,etal.Effects of multistrain probiotic containing yogurt on second line tripletherapy for Helicobacter pylori infection[J].J.Gastroenterol.Hepatol., 2011,26:44-48),其中乳酸菌的应用最为广泛。
乳酸菌是国内外公认的对人类健康有益的安全(generally recognized assafe,GRAS)微生物,被广泛应用于食品、医药、农业等领域中,能够调节胃肠道菌群平衡,提高人体免疫力,改善机体营养状况,还具有降低胆固醇、血脂等多种生理功能。很多乳酸菌还能够产生对致病微生物具有拮抗作用的物质,如有机酸类、乙醇、过氧化氢、罗伊氏菌素、细菌素类等,在食品以及医药等行业具有潜在的应用价值,是乳酸菌研究热点之一 (王彦伟.产细菌素乳酸菌的筛选及其所产细菌素leucocin B-K7的研究[D].江南大学, 2016)。
幽门螺杆菌之所以能在酸度很低的胃中存活,就是因为幽门螺杆菌能产生脲素酶。脲素酶可将体内的脲素等分解为氨和二氧化碳,从而使幽门螺杆菌周围环境的pH值上升,形成一个微环境使幽门螺杆菌能够稳定生存增殖。因此,如果能找到抑制幽门螺杆菌脲素酶活性的益生菌加到幽门螺杆菌所处的环境中,将使幽门螺杆菌处于不利的生存环境,从而抑制幽门螺杆菌在胃中的定植与生长(陈晓华.拮抗幽门螺杆菌益生菌的筛选及其干预机制的研究[D].江南大学,2011)。
乳酸菌中明串珠菌属的肠膜明串珠菌(Leuconostoc mesenteroides)是重要菌种,安全性高(李祎,吴晓敏,杜航,景如贤,杨刚刚.一株肠膜明串珠菌的分离鉴定及其抑菌特性[J].微生物学通报,2021,48(12):4776-4788)。José从蔬菜中分离和纯化得到的肠膜明串珠菌能够有效抑制尖孢镰刀菌的生长(LinaresMorales JoséRafael et al.Selection of Lactic Acid Bacteria Isolated from Fresh Fruits and VegetablesBased on Their Antimicrobial and Enzymatic Activities.[J].Foods(Basel,Switzerland), 2020,9(10):1399-1399)。苏慧慧从鲜榨蔗汁中分离和纯化后得到的肠膜明串珠菌,对几种食源性致病菌如金黄色葡萄球菌、大肠杆菌、沙门氏菌和单增李斯特菌有抑菌效果(苏慧慧,高亚飞,张平军,黄俊生,郭艺山,黄冬婷,高俊永,徐日益,刘芷媛.一种产细菌素的肠膜明串珠菌及其应用[P].CN113308408A,2021-08-27),未见有肠膜明串珠菌对幽门螺杆菌抑制或应用的研究,也未见其与小球藻、甘油、甜菊糖配伍后在增效抑制幽门螺杆菌的食品、保健品或药用辅料中的应用。
小球藻(Chlorella)属绿藻门(Chlorophyta)绿球藻目(Chlorococcales)小球藻科(Chlorellales),可直接作为膳食补充剂。小球藻中多糖、酚酸类和黄酮类具有多种生物活性,可调节机体免疫力和抗肿瘤、抗炎、抗病毒、抗菌、抗氧化等。有的多糖已被纯化作为新一代药物(谢凤行,周可,张峰峰,赵琼,赵玉洁,杨建永,孙丽丽.小球藻培养基优化及脱氮效果[J].天津师范大学学报(自然科学版),2019,39(05):51-56;孙建瑞,赵君峰,符丹丹,原江锋,王大红.响应面法优化Chlorella vulgaris224胞外多糖积累及其抑菌和抗氧化活性[J].天然产物研究与开发,2020,32(03):489-497)。小球藻的甲醇提取物有抑制大肠杆菌和金黄色葡萄球菌的作用(Pradhan Biswajita et al. Evaluation of the anti-bacterial activity of methanolic extract of Chlorella vulgaris Beyerinck[Beijerinck]with special reference to antioxidant modulation[J].FutureJournal of Pharmaceutical Sciences,2021,7(1):145-146)。
甜菊糖可促进小球藻的生长,提高生长速度和培养效率(陈育如,尹慧慧,郭欢欢等. 甜菊糖在促进小球藻生长中的应用[P].ZL107043733B):添加来自生物质热解的内醚糖或经脱毒处理的纤维素热解液也能促进小球藻生长并且提高其叶绿素和单细胞蛋白含量。内醚糖或热解液能促进小球藻的生长的效率最高达194%,并显著提高其叶绿素和菌体蛋白含量(陈育如,孙欢,赵乙萱,刘军利,卫民.一种促进小球藻生长并提高其叶绿素和菌体蛋白含量的方法[P].ZL 103045481B)。
发明内容
本发明在常用食品霉豆渣中筛选了多种乳酸菌和真菌,其中一株乳酸菌能有效抑制 HP菌的生长(经形态和分子生生物学鉴定为肠膜明串珠菌(LK-06),并提交菌种保藏中心保藏,保藏号为CGMCC No.24366,将其与小球藻、甜菊糖、甘油等配伍使用,大大提高了对HP菌的抑制效率。
一方面,本申请提供了一种具有抑制幽门螺旋杆菌和其脲素酶活性的肠膜明串珠菌 LK-06,所述肠膜明串珠菌已于2022年1月25日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.24366,保藏地址为北京市朝阳区北辰西路1号院3号。
进一步地,本申请提供了上述肠膜明串珠菌CGMCC No.24366以及可选的甘油或甘油前体在制备抑制幽门螺杆菌和/或抑制幽门螺杆菌脲素酶活性的产品中的应用。
另一方面,本申请提供了抑制幽门螺杆菌和/或抑制幽门螺杆菌脲素酶活性的产品,其包含上述肠膜明串珠菌CGMCC No.24366以及可选的甘油或甘油前体。
进一步地,所述产品中肠膜明串珠菌的活菌数不低于5×105CFU/mL或5×105CFU/g。
进一步地,所述产品选自药物、食品、保健品、药物载体和/或药用辅料。
进一步地,所述产品为冲饮剂、片剂、丸剂、粉剂、口服液、颗粒剂或胶囊剂。
进一步地,所述产品为益生菌压片、益生菌固体饮料、益生菌液体饮料、益生菌糖果、益生菌牙膏、益生菌酸奶、益生菌功能性保健品、益生菌药用辅料。
进一步地,所述产品中还包括选自小球藻粉、小球藻其提取物或藻液、植物油、全脂或脱脂奶粉、豆奶粉、甜菊糖、酶改糖、木糖醇、微晶纤维素、硬脂酸镁、全脂乳粉、脱脂乳粉、豆乳粉、豆粉、豆浆、其他益生菌的成分。
另一方面,本申请提供了一种抑制幽门螺杆菌和/或抑制幽门螺杆菌脲素酶活性的产品,其特征在于,所述产品包含肠膜明串珠菌菌株CGMCC No.24366与甘油或甘油前体,其中肠膜明串珠菌菌株CGMCC No.24366与甘油或甘油前体混合存在或分装在不同容器或药剂中联合使用。
进一步地,甘油或甘油前体使用时的浓度为50-300mmol/L,优选100-300mmol/L,优选200-300mmol/L,最优选300mmol/L。
另一方面,本申请提供了一种抑制幽门螺杆菌和/或脲素酶活性的产品,其特征在于,所述产品包含肠膜明串珠菌菌株CGMCC No.24366与小球藻,其中肠膜明串珠菌菌株CGMCC No.24366与小球藻混合存在或分装在不同容器或药剂中联合使用,其中小球藻占产品重量的5%-30%。
所用甜菊糖可以是甜菊糖苷系列物中的一种或多种混合物。
所用甘油既可以是不同浓度或纯度的产品,也可以是能在体内产生甘油的前体如甘油脂等。
本申请提供了一种肠膜明串珠菌肠膜亚种(Leuconostoc mesenteroides)CGMCCNo.24366,并提供了该菌及其与甘油的组合在抑制幽门螺杆菌中的应用。肠膜明串珠菌CGMCC No.24366可显著抑制幽门螺杆菌的生长(抑菌圈直径12.6mm);也可显著抑制幽门螺旋杆菌脲素酶的活性(抑制率68.3%);与甘油合用,抑制幽门螺杆菌能力显著提高(抑菌圈直径14.4mm);在制备抑制幽门螺杆菌的产品,如食品、保健品和药用辅料等中具有良好的应用前景。
附图说明
图1为不同菌株抑制HP菌脲素酶活力的比较图;
图2为肠膜明串珠菌加甘油前后的抑菌效果比较图(左为加甘油处理前的抑菌圈,右为加甘油处理后的抑菌圈。
具体实施方式
实施例1:
肠膜明串珠菌对幽门螺杆菌的抑制作用
肠膜明串珠菌CGMCC No.24366接种于MRS液体培养基中,37℃条件培养培养12h得到菌液。用牛津杯法测定菌液抑制幽门螺杆菌的效果,肠膜明串珠菌CGMCC No.24366 菌液对幽门螺杆菌的抑菌圈达12.6mm,表明肠膜明串珠菌CGMCC No.24366具有很强的抑制幽门螺杆菌的作用。
实施例2:
甘油增效肠膜明串珠菌对幽门螺杆菌的抑制作用
肠膜明串珠菌CGMCC No.24366接种于MRS液体培养基中,37℃条件培养培养12h得到菌液。用牛津杯法测定甘油增效肠膜明串珠菌CGMCC No.24366抑制幽门螺杆菌的效果,一只牛津杯只加肠膜明串珠菌CGMCC No.24366菌液,另一只牛津杯加入肠膜明串珠菌CGMCC No.24366菌液和甘油(300mmol/L),肠膜明串珠菌CGMCC No.24366菌液对幽门螺杆菌的抑菌圈达12.6mm,肠膜明串珠菌CGMCC No.24366菌液和甘油对幽门螺杆菌的抑菌圈达14.4mm,表明甘油增效肠膜明串珠菌CGMCC No.24366对幽门螺杆菌的抑制作用。
实施例3:
肠膜明串珠菌等乳酸菌对幽门螺杆菌脲素酶活力的影响
肠膜明串珠菌接种于MRS培养基中经培养得发酵液。在96孔板中,取800μL幽门螺杆菌和200μL肠膜明串珠菌悬液混匀,共培养6h、22h。然后取50μL加入150μL脲素-酚红溶液,振荡后于波长550nm处测其吸光度值。图1的结果表明,经肠膜明串珠菌 CGMCCNo.24366处理后,幽门螺杆菌的脲素酶活力显著下降(抑制率68.3%)。表明肠膜明串珠菌CGMCC No.24366可有效降低幽门螺杆菌脲素酶的活力。
实施例4:
肠膜明串珠菌对幽门螺杆菌阳性患者幽门螺杆菌量和清除率的影响
30名幽门螺杆菌阳性感染者(人群分布情况见表1,随机分为两组,人群基本情况差异无统计学意义),其中,服用安慰剂组15人,服用肠膜明串珠菌CGMCC No.24366益生菌剂组15人。安慰剂组每天服用安慰剂3次,肠膜明串珠菌CGMCC No.24366益生菌组每天服用菌剂3次,实验周期1个月(安慰剂和肠膜明串珠菌菌粉除成分不同外,产品的外观和包装均相同,无明显差别)。分别于实验开始前和结束后通过C13吹气实验和HP检测试纸检测安慰剂组和益生菌组人员,评估患者体内幽门螺杆菌的清除率。
由表1可见,肠膜明串珠益生菌组阴性率显著高于安慰剂组。此结果表明,肠膜明串珠菌CGMCC No.24366对提高幽门螺杆菌感染患者体内幽门螺杆菌的清除率有帮助。
表1不同组别幽门螺杆菌阳性患者的清除率
实施例5:
菌粉冻干制备
肠膜明串珠菌CGMCC No.24366接种于液体发酵培养基中,37℃条件下培养36h得到菌液;经8000rpm离心10min得到菌泥;加保护剂后冻干,得到肠膜明串珠菌CGMCCNo.24366菌粉;保护剂的成分包含:100g/L脱脂奶粉。
实施例6:
菌粉喷雾干燥制备
肠膜明串珠菌CGMCC No.24366接种于液体发酵培养基中,35℃条件下培养得到菌液;加保护剂后,用常规喷雾干燥工艺得到肠膜明串珠菌CGMCC No.24366菌粉;保护剂的成分包含:100g/L脱脂奶粉。
实施例7:
胶囊剂制备制备过程如下:
肠膜明串珠菌CGMCC No.24366菌粉25份、糊精54份、羧甲基淀粉钠15份、脱脂乳粉3份,小球藻2份,甜菊糖苷1份,混合均匀后用胶囊机分装得胶囊产品。
实施例8:
肠膜明串珠菌CGMCC No.24366菌粉25份、糊精54份、羧甲基淀粉钠15份、脱脂乳粉3份,小球藻2份,甜菊糖苷1份,加成型剂混合均匀后用压片机压片得片剂产品。
实施例9:
肠膜明串珠菌CGMCC No.24366菌粉15份、罗伊氏菌10份,糊精54份、羧甲基淀粉钠15份、脱脂乳粉3份,小球藻2份,甜菊糖苷酶改煻1份,加成型剂混合均匀后,用压片机压片得片剂产品。
实施例10:
肠膜明串珠菌CGMCC No.24366菌粉15份、约氏乳杆菌10份,糊精54份、羧甲基淀粉钠15份、脱脂乳粉3份,小球藻2份,甜菊糖苷酶改煻1份,加成型剂混合均匀后,用压片机压片得片剂产品。
实施例11:
肠膜明串珠菌CGMCC No.24366菌粉15份、鼠李乳杆菌粉10份,糊精54份、羧甲基淀粉钠15份、脱脂乳粉3份,小球藻2份,甜菊糖苷酶改煻1份,加成型剂混合均匀后,用压片机压片得片剂产品。
实施例12:
其他同实施例11,将其中的鼠李乳杆菌换为嗜酸乳杆菌。
实施例13:
肠膜明串珠菌CGMCC No.24366制备口服液,具体过程如下:
量取肠膜明串珠菌CGMCC No.24366菌液97份、甜菊酶改糖2份、小球藻提取物1份,抗坏血酸0.05份混合罐装,即得口服液。
实施例14:
制备口服液,具体制备过程如下:
量取肠膜明串珠菌CGMCC No.24366菌液80份、鼠李糖乳杆菌菌液10份、、甜菊糖 1份、抗坏血酸0.05份混合罐装,即得口服液。
实施例15:
肠膜明串珠菌CGMCC No.24366菌液84份、罗伊氏乳杆菌菌液15份、甜菊糖1份、抗坏血酸0.05份混合均匀,罐装即得液体饮料。
实施例16:
其他同实施例15,将其中的罗伊氏乳杆菌换为嗜酸乳杆菌。
实施例17:
肠膜明串珠菌CGMCC No.24366用于制备压片糖果过程如下:
将下述原料包括脱脂奶粉30份、肠膜明串珠菌CGMCC No.24366的菌粉25份、约氏乳杆菌菌液15份,糊精35份、植物油10份、甜菊糖2.5份、微晶纤维素8份和硬脂酸镁1份混合过150目筛网,通过压片机压片,包装,制得益生菌无糖压片糖果。
实施例18:
其他同实施例17,将其中的嗜酸乳杆菌换为约氏乳杆菌。
实施例19:
肠膜明串珠菌CGMCC No.24366可用于制备压片糖果,具体制备过程如下:
将下述原料包括脱脂奶粉30份、肠膜明串珠菌CGMCC No.24366的菌粉15份、糊精35 份、植物油10份、甘油5份、甜菊糖2份、微晶纤维素8份和硬脂酸镁2份混合过150 目筛网,通过压片机压片后包装。
实施例20:
将全脂奶粉30份、肠膜明串珠菌CGMCC No.24366的菌粉3份、鼠李糖乳杆菌2份、精精35份、小球藻10份、甜菊糖4份、微晶纤维素8份和硬脂酸镁1份混合过150目筛网,通过压片机压片,包装,制得益生菌无糖片剂。
实施例21:
肠膜明串珠菌CGMCC No.24366用于制备固体饮料,具体制备过程如下:
肠膜明串珠菌CGMCC No.24366的菌粉18份、罗伊氏乳杆菌12份、乳粉35份、甜菊糖2份、CMC混合后包装,制得益生菌固体饮料。
实施例22:
肠膜明串珠菌CGMCC No.24366可用于制备药用辅料,过程如下:
肠膜明串珠菌CGMCC No.24366的菌粉50份、甜菊酶改糖50份、混合均匀后作为药用辅料。
实施例23:
肠膜明串珠菌CGMCC No.24366用于制备益生菌酸奶:
脱脂奶在灭菌后冷却,添加5%肠膜明串珠菌CGMCC No.24366菌粉和乳酸菌菌粉,1%甜菊糖苷,得到益生菌酸奶。
实施例24:
肠膜明串珠菌CGMCC No.24366可用于制备益生菌酸奶,具体制备过程如下:
全脂奶巴氏杀菌后添加5%肠膜明串珠菌CGMCC No.24366菌粉,4%小球藻粉,1%甜菊糖苷,得到益生菌小球藻酸奶。
实施例25:
脱脂奶在95℃热杀菌20min后冷却,添加3%肠膜明串珠菌CGMCC No.24366菌粉,2%鼠李糖乳杆菌菌粉,1%甜菊糖苷,混合均质罐装,得到益生菌饮料。
实施例26:
新鲜牛奶在95℃热杀菌20min后冷却,添加4%肠膜明串珠菌CGMCC No.24366菌粉, 1%罗伊氏乳杆菌菌粉,2%甜菊糖苷,混合,均质罐装,得到益生菌奶。
实施例27:
脱脂奶在95℃热杀菌20min后冷却,得到原料;在原料中添加3%肠膜明串珠菌CGMCC No.24366菌粉,2%嗜酸乳杆菌菌粉,2%甜菊糖苷,混合,均质罐装,得到益生菌奶。
实施例28:
肠膜明串珠菌CGMCC No.24366用于制备益生菌牙膏,具体制备过程如下:
肠膜明串珠菌CGMCC No.24366 25份加入甜菊糖苷1份、去离子水40份,均匀搅拌获得的胶体,再加入发泡剂5份进行搅拌,再抽真空获得混合膏体,加入3份的薄荷香精并搅拌均匀,室温静置,经包装后得牙膏产品。
实施例29:
肠膜明串珠菌CGMCC No.24366 25份加入小球藻粉5份、甜菊糖苷2份、去离子水40份,均匀搅拌获得的胶体,再加入发泡剂5份进行搅拌,再抽真空获得混合膏体,加入3份的薄荷香精并搅拌均匀,室温静置后包装得牙膏产品。
实施例30:
肠膜明串珠菌CGMCC No.24366 25份加入甘油10份、甜菊糖苷2份、去离子水40份,均匀搅拌获得的胶体,再加入发泡剂5份进行搅拌,再抽真空获得混合膏体,加入3 份的薄荷香精并搅拌均匀,室温静置后包装得牙膏产品。
实施例31:
肠膜明串珠菌CGMCC No.24366 15份,鼠李糖乳杆菌10份,加入甜菊糖苷2份、去离子水40份,均匀搅拌获得的胶体,再加入发泡剂5份进行搅拌,再抽真空获得混合膏体,加入3份的薄荷香精并搅拌均匀,室温静置包装后得牙膏产品。
实施例32:
肠膜明串珠菌CGMCC No.24366 13份,罗伊氏乳杆菌12份,加入甜菊糖苷2份、去离子水40份,均匀搅拌获得的胶体,再加入发泡剂5份进行搅拌,再抽真空获得混合膏体,加入3份的薄荷香精并搅拌均匀,室温静置包装后得牙膏产品。
实施例33:
肠膜明串珠菌CGMCC No.24366 10份,嗜酸乳杆菌15份,加入甜菊糖苷2份、去离子水 40份,均匀搅拌获得的胶体,再加入发泡剂5份进行搅拌,再抽真空获得混合膏体,加入3份的薄荷香精并搅拌均匀,室温静置包装后得牙膏产品。
实施例34:
肠膜明串珠菌CGMCC No.24366接种于MRS液体培养基,37℃条件培养培养12h得到菌液。图2显示了用牛津杯法测定甘油增效肠膜明串珠菌CGMCC No.24366抑制幽门螺杆菌的效果,一只牛津杯只加肠膜明串珠菌CGMCC No.24366菌液,另一只牛津杯加入肠膜明串珠菌CGMCC No.24366菌液和小球藻提取物(占菌液的5%),与未加小球藻的肠膜明串珠菌CGMCC No.24366菌液,相比,加有小球藻提取物的抑菌圈更大(直径增加了 22%),说明小球藻提取物能增效肠膜明串珠菌CGMCC No.24366对幽门螺杆菌的抑制作用。
显然,本发明的上述实施例仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而这些属于本发明的精神所引伸出的显而易见的变化或变动仍处于本发明的保护范围之中。
Claims (15)
1.一种具有抑制幽门螺旋杆菌和其脲素酶活性的肠膜明串珠菌LK-06(Leuconostocmesenteroides),所述肠膜明串珠菌保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.24366。
2.根据权利要求1所述的肠膜明串珠菌以及可选的甘油或甘油前体在制备抑制幽门螺杆菌和/或抑制幽门螺杆菌脲素酶活性的产品中的应用。
3.抑制幽门螺杆菌和/或脲素酶活性的产品,其包含根据权利要求1所述的肠膜明串珠菌CGMCC No.24366以及可选的甘油或甘油前体。
4.一种抑制幽门螺杆菌和/或脲素酶活性的产品,其特征在于,所述产品包含肠膜明串珠菌菌株CGMCC No.24366与甘油或甘油前体,其中肠膜明串珠菌菌株CGMCC No.24366与甘油或甘油前体混合存在或分装在不同容器或药剂中联合使用。
5.一种抑制幽门螺杆菌和/或脲素酶活性的产品,其特征在于,所述产品包含肠膜明串珠菌菌株CGMCC No.24366与小球藻,其中肠膜明串珠菌菌株CGMCC No.24366与小球藻混合存在或分装在不同容器或药剂中联合使用,其中小球藻占产品质量的5%-30%。
6.根据权利要求2所述的应用或3-4任一项所述的产品,其中所述产品中肠膜明串珠菌的活菌数不低于5×105CFU/mL或5×105CFU/g。
7.根据权利要求2所述的应用或3-4任一项所述的产品,其中所述产品选自药物、食品、保健品、药物载体和/或药用辅料。
8.根据权利要求2所述的应用或3-4任一项所述的产品,其中所述产品为冲饮剂、片剂、丸剂、粉剂、口服液、颗粒剂或胶囊剂。
9.根据权利要求2所述的应用或3-4任一项所述的产品,其中所述产品为益生菌压片、益生菌固体饮料、益生菌液体饮料、益生菌糖果、益生菌牙膏、益生菌酸奶、益生菌功能性保健品、益生菌药用辅料。
10.根据权利要求2所述的应用或3-8任一项所述的产品,其中所述产品中还包括选自小球藻粉、小球藻其提取物或藻液、植物油、全脂或脱脂奶粉、豆奶粉、甜菊糖、酶改糖、木糖醇、微晶纤维素、硬脂酸镁、全脂乳粉、脱脂乳粉、豆乳粉、豆粉、豆浆、其他益生菌的成分。
11.根据权利要求10所述的应用或产品,其中所述甜菊糖为甜菊糖苷系列物中的一种或多种混合物。
12.根据权利要求2所述的应用或3-10任一项所述的产品,其中甘油或甘油前体使用时的浓度为50-300mmol/L。
13.根据权利要求12所述的产品或应用,其中甘油或甘油前体使用时的浓度为200-300mmol/L。
14.根据权利要求13所述的产品或应用,其中甘油或甘油前体使用时的浓度为300mmol/L。
15.根据权利要求1-14任一项所述的产品或应用,其中所述甘油前体为甘油脂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210731354.8A CN115094001B (zh) | 2022-06-24 | 2022-06-24 | 肠膜明串珠菌及其在制备抑制幽门螺杆菌的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210731354.8A CN115094001B (zh) | 2022-06-24 | 2022-06-24 | 肠膜明串珠菌及其在制备抑制幽门螺杆菌的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115094001A true CN115094001A (zh) | 2022-09-23 |
CN115094001B CN115094001B (zh) | 2023-09-26 |
Family
ID=83292148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210731354.8A Active CN115094001B (zh) | 2022-06-24 | 2022-06-24 | 肠膜明串珠菌及其在制备抑制幽门螺杆菌的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115094001B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100707102B1 (ko) * | 2006-07-07 | 2007-04-16 | 주식회사 두산 | 헬리코박터 파이로리 및 유해미생물의 증식을 억제하는 김치 유산균, 이를 이용한 김치의 제조방법 및 이의 용도 |
KR20130002533A (ko) * | 2011-06-29 | 2013-01-08 | 주식회사 비케이바이오 | 헬리코박터 파이로리의 생육을 저해하는 김치 유래 젖산균 |
JP2013116089A (ja) * | 2011-12-05 | 2013-06-13 | Nagoya Seiraku Kk | 抗ヘリコバクター・ピロリ効果を有する乳酸菌株、その乳酸菌株を含む抗ヘリコバクター・ピロリ剤、及びその乳酸菌株を含む飲食品 |
CN112430553A (zh) * | 2020-11-25 | 2021-03-02 | 山东向日葵生物工程有限公司 | 一株具有抑制幽门螺杆菌功能的罗伊氏乳杆菌sf-l-25及其应用 |
CN112458020A (zh) * | 2020-12-04 | 2021-03-09 | 嘉兴益诺康生物科技有限公司 | 一种抑制幽门螺杆菌的益生菌组合物及应用 |
CN113412060A (zh) * | 2018-12-28 | 2021-09-17 | Cj第一制糖株式会社 | 用于预防或治疗幽门螺杆菌相关疾病的泡菜 |
-
2022
- 2022-06-24 CN CN202210731354.8A patent/CN115094001B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100707102B1 (ko) * | 2006-07-07 | 2007-04-16 | 주식회사 두산 | 헬리코박터 파이로리 및 유해미생물의 증식을 억제하는 김치 유산균, 이를 이용한 김치의 제조방법 및 이의 용도 |
KR20130002533A (ko) * | 2011-06-29 | 2013-01-08 | 주식회사 비케이바이오 | 헬리코박터 파이로리의 생육을 저해하는 김치 유래 젖산균 |
JP2013116089A (ja) * | 2011-12-05 | 2013-06-13 | Nagoya Seiraku Kk | 抗ヘリコバクター・ピロリ効果を有する乳酸菌株、その乳酸菌株を含む抗ヘリコバクター・ピロリ剤、及びその乳酸菌株を含む飲食品 |
CN113412060A (zh) * | 2018-12-28 | 2021-09-17 | Cj第一制糖株式会社 | 用于预防或治疗幽门螺杆菌相关疾病的泡菜 |
CN112430553A (zh) * | 2020-11-25 | 2021-03-02 | 山东向日葵生物工程有限公司 | 一株具有抑制幽门螺杆菌功能的罗伊氏乳杆菌sf-l-25及其应用 |
CN112458020A (zh) * | 2020-12-04 | 2021-03-09 | 嘉兴益诺康生物科技有限公司 | 一种抑制幽门螺杆菌的益生菌组合物及应用 |
Non-Patent Citations (3)
Title |
---|
SR RAHAYUNINGSIH ET AL.: "study of leuconostoc mesenteroides as potential probiotic for anti helicobacter pylori", PROCEEDINGS THE 7TH INERNATIONAL SYMPOSIUM FOR SUSTAINABLE HUMANOSPHERE, pages 1 - 216 * |
SUNG-MEE LIM: "Anti-Helicobacter pylori activity of antimicrobial substances produced by lactic acid bacteria isolated from baikkimchi", JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY, vol. 57, no. 5, pages 621 - 630 * |
YOUNG DUCK LEE ET AL.: "antimicrobial effect of lactic acid bacteria isolated from kimchi and tarak on helicobacter pylori", THE KOREAN JOURNAL OF FOOD AND NUTRITION, vol. 23, no. 4, pages 664 - 669, XP053009770 * |
Also Published As
Publication number | Publication date |
---|---|
CN115094001B (zh) | 2023-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100778886B1 (ko) | 과채발효물의 제조방법, 그 방법으로 제조된 과채발효물 및이를 포함하는 기능성 조성물 | |
KR101287120B1 (ko) | 락토바실러스 플란타륨 dsr ck10또는 락토바실러스 플란타륨 dsr m2를 유효성분으로 함유하는 암 치료용 조성물 | |
KR101398249B1 (ko) | 항암 또는 항균 활성을 가지는 락토바실러스 플란타룸 피엠오08 및 식물성 원재료를 이용한 유산균 발효제품의 제조방법 | |
CN107530387B (zh) | 含有双歧杆菌和十字花科蔬菜的经口组合物 | |
KR20180014316A (ko) | 다양한 생리활성과 열 안정성이 우수한 프로바이오틱 락토바실러스 퍼멘텀 pl9119 | |
JP2003250528A (ja) | ビフィドバクテリウム属細菌の生残性改善剤、増殖促進剤、又は、同細菌含有醗酵物の製造方法 | |
KR101000364B1 (ko) | 생존율 증강용 이중 코팅 방법 | |
KR101394322B1 (ko) | 신규한 바실러스 서브틸리스 bcnu 9169 균주 및 이를 유효성분으로 포함하는 생균제 조성물 | |
KR20230037529A (ko) | 김치 유산균을 이용한 포스트바이오틱스 제조 방법 | |
CN105802876B (zh) | 一种复合益生菌发酵苜蓿嫩芽粉制剂及其制备方法和应用 | |
KR20190002036A (ko) | 블루베리 추출물을 포함하는 장내 유익균의 증식을 위한 프리바이오틱스 및 이의 용도 | |
KR101472190B1 (ko) | 식물성 유산균 락토바실러스 플란타룸 피엠오08 사균체를 유효성분으로 포함하는 변비 예방, 치료 또는 개선용 조성물 | |
KR101605085B1 (ko) | 개똥쑥 발효환 및 그 제조방법 | |
KR101473421B1 (ko) | 과민성대장증후군 개선용 조성물 | |
KR20170120264A (ko) | 프로바이오틱스 유산균을 활용한 밤 발효 퓨레 및 이를 포함하는 식품조성물 | |
KR20200070081A (ko) | 충치 억제 활성을 갖는 락토바실러스 살리바리우스를 포함하는 조성물 | |
KR101905322B1 (ko) | 유산균을 포함하는 면역 증강용 조성물 | |
CN115094001B (zh) | 肠膜明串珠菌及其在制备抑制幽门螺杆菌的药物中的应用 | |
JP2012187015A (ja) | イグサ加工食品 | |
KR102562888B1 (ko) | 면역력에 도움을 주는 김치 유산균을 이용한 마늘 포스트바이오틱스 제조 방법 | |
KR101776511B1 (ko) | 락토바실러스 플란타룸으로 발효시킨 향나무 열매 배양액의 리스테리아 항균조성물 | |
KR102244732B1 (ko) | 프로바이오틱 초산균인 아세토박터 파스테리아누스 mglv 및 이의 면역조절 효과 | |
JPS63291579A (ja) | ビフィドバクテリウム菌の増殖促進剤 | |
KR20200070080A (ko) | 충치 억제 활성을 갖는 락토바실러스 루테리 mg505 를 포함하는 조성물 | |
KR100711256B1 (ko) | 유산균을 함유하는 미세과립 및 그의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |